Announcement Summary

Entity name

NOXOPHARM LIMITED

Announcement Type

New announcement

Date of this announcement

3/11/2026

The Proposed issue is:
An offer of securities under a securities purchase plan

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	OPTION EXPIRING 1-NOV-2027 EX $0.042	23,809,524
NOX	ORDINARY FULLY PAID	23,809,524

+Record date

30/10/2026

Offer closing date

7/12/2026

+Issue date

11/12/2026

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

NOXOPHARM LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type	**Registration Number**
ABN	50608966123

1.3 ASX issuer code

NOX

1.4 The announcement is
New announcement

1.5 Date of this announcement

3/11/2026

1.6 The Proposed issue is:
An offer of +securities under a +securities purchase plan

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?

Yes

4A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
Other (please specify in comment section)	23/11/2026	Estimated	

Comments

The issue of the Attaching Options and piggyback Options are subject to offer under a Prospectus.

Part 4B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

NOX : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?
Yes

Details of +securities proposed to be issued

ASX +security code and description

NOX : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

23,809,524

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?
No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?
No

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?
Yes

Is the minimum acceptance unit based or dollar based?
Dollar based ($)

Please enter the minimum acceptance value

$ 2,500

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?
Yes

Is the maximum acceptance unit based or dollar based?
Dollar based ($)

Please enter the maximum acceptance value

$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

$2,500, $5,000. $10,000, $15,000, $20,000, $25,000, $30,000

Offer price details

Has the offer price been determined?
Yes

In what currency will the offer be made?	What is the offer price per +security?
AUD - Australian Dollar	AUD 0.04200

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?
Yes

Describe the scale back arrangements

The SPP aims to raise approximately $1.0 million. Noxopharm may determine to raise a higher amount or decide to scale back Applications under the SPP at its absolute discretion.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Attaching +Security

The proposed attaching security can only be of an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)
New class

Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?
No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?
Yes

ASX +security code	+Security description
New class-code to be confirmed	OPTION EXPIRING 1-NOV-2027 EX $0.042

+Security type

Options

Offer ratio (ratio of attaching securities at which the new +securities will be issued)

The quantity of attaching +securities to be issued	For a given quantity of the new +securities issued
1	1

What will be done with fractional entitlements?

Fractions over 0.5 rounded up

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

23,809,524

Offer price details

Has the offer price been determined?

Yes

In what currency will the offer be made?

AUD - Australian Dollar

What is the offer price per +security?

AUD 0.00000

Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan

Yes

Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS

Yes

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

The SPP aims to raise approximately $1.0 million. Noxopharm may determine to raise a higher amount or decide to scale back Applications under the SPP at its absolute discretion.

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency

AUD - Australian Dollar

Exercise price

AUD 0.0630

Expiry date

1/11/2029

Details of the type of +security that will be issued if the option is exercised

NOX : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

If a Piggyback Option is exercised, the following securities will be issued:
(a) 1 Ordinary Share (ASX: NOX)

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer ASX Release date 2 November 2026.

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

2/11/2026

4C.2 +Record date

30/10/2026

4C.3 Date on which offer documents will be made available to investors

23/11/2026

4C.4 Offer open date

23/11/2026

4C.5 Offer closing date

7/12/2026

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

11/12/2026

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

Yes

4E.1a Who is the lead manager/broker?

Pac Partners Securities Pty Ltd

4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

1. 6.0% + GST cash fee on Funds raised (unrelated SPP)

4E.2 Is the proposed offer to be underwritten?

No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

N/A

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Refer to ASX announcement dated 2 Nov 26. Undertaking the SOF-SKN extension study, Planned activities for IND application for SOF-SKN Phase 2 trial, SOF-CAN and SOF-VAC preclinical development (including in vivo studies), Working capital.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

Eligible Share Holder has a registered address either in Australia or NZ (provided the Holder is not in USA, or acting for the account or benefit of a US Person). Holders in Denmark,Germany,Greece,HK,Netherlands, Singapore,UK and USA who are not eligible.

4F.3 URL on the entity's website where investors can download information about the proposed offer

www.noxopharm.com

4F.4 Any other information the entity wishes to provide about the proposed offer

N/A